STRO — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-12

• We initiated this Phase 1 trial in November 2025 at U.S.-only sites. The trial includes heavily pretreated patients (median of 3 prior lines of therapy [range 1–7]) across eight tumor types unselected for TF expression. In pancreatic and colorectal cancer patients, 100% of patients received one or m…

• Key observations as of the data cutoff date of July 24, 2026 for this trial include:

• Multiple responses, including confirmed and ongoing unconfirmed partial responses, across three tumor types in RECIST-evaluable patients to date; including pancreatic cancer, head and neck cancer, and non-small cell lung cancer at the 3 and 4 mg/kg dose levels.

• Favorable tolerability profile, with mostly low-grade adverse events (AEs) observed. Overall discontinuation rate due to AEs was low at 6%.

• All-grade treatment related adverse events (TRAEs) that occurred in more than 15% of patients were nausea (33%), fatigue (29%), and anemia (18%).

Text removed vs the prior filing · source: 10-Q · 2026-05-14

• Our preclinical assets include STRO-227 and STRO-006. STRO-006 is an ADC targeting Integrinß6, or ITGß6. We believe STRO-006 has the potential to be a best-in-class ADC targeting ITGß6 based on preclinical studies that have demonstrated potent antitumor activity and the potential for a differentiate…

• STRO-227 is our first wholly-owned dual-payload ADC, targeting Protein Tyrosine Kinase 7, or PTK7. This approach incorporates two distinct cytotoxic payloads, one that is designed to inhibit tubulin and another that is designed to inhibit

• topoisomerase. We have initiated certain chemistry, manufacturing and controls, or CMC, related activities for the PTK7-targeting dual-payload ADC and anticipate submitting an IND in connection with this program in late 2026.

• Enabled through our proprietary XpressCF® and XpressCF+® platforms, we have entered into multitarget, product-focused collaborations with leading pharmaceutical and biotechnology companies in the field of oncology and we may enter into additional such collaborations in the future. We have an ongoing…

• marketing, manufacturing and distribution. We expect a reduction in operating expenses as we strategically reprioritize our resources. However, we anticipate our operating expenses would increase as we advance our product candidates through clinical development, seek regulatory approvals for our pro…

Text added vs the prior filing · source: 10-Q · 2026-08-12

• The rapid advancement and widespread availability of artificial intelligence technologies have significantly increased the capabilities of cyber threat actors. Generative AI and other AI-enabled tools can be used to automate reconnaissance, identify vulnerabilities, generate highly convincing phishi…

• As a biotechnology company, we maintain valuable intellectual property, proprietary manufacturing processes, preclinical and clinical research data, regulatory information and confidential business information that may make us an attractive target for sophisticated cyber threat actors, including nat…

• We take steps designed to detect, mitigate, and remediate vulnerabilities in our information systems. We have not and may not in the future, however, detect and remediate all such vulnerabilities in our information technology systems, including on a timely basis, because such threats and techniques …

• Moreover, if a computer security breach affects our systems or results in the unauthorized release of personal information, our reputation could be materially damaged, we may be required to formally notify governmental agencies,

• the media or individuals pursuant to various federal and state privacy and security laws. We could also be exposed to a risk of loss or litigation and potential liability under laws, regulations and contracts that protect the privacy and security of personal information that may result in regulatory…

Text removed vs the prior filing · source: 10-Q · 2026-05-14

• The risk of a formal security breach or disruption or data loss, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions fro…

• We take steps designed to detect, mitigate, and remediate vulnerabilities in our information systems. We have not and may not in the future, however, detect and remediate all such vulnerabilities in our information technology systems, including on a timely basis, because such threats and techniques …

• network connections outside our premises, including while at home, or in transit and in public locations, this poses increased risks to our information technology systems and data.

• Moreover, if a computer security breach affects our systems or results in the unauthorized release of personal information, our reputation could be materially damaged, we may be required to formally notify governmental agencies, the media or individuals pursuant to various federal and state privacy …

• We may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets of our employees’ or consultants’ former employers or their clients. These claims may be